CLAIMS

1. A vaccine composition comprising a flavivirus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs: 1 to 11 or a variant thereof.

2. A vaccine composition according to Claim 1, in which the flavivirus peptide is attached to a nanoparticle.

3. A vaccine composition according to Claim 2, in which the nanoparticle is a gold nanoparticle, a calcium phosphate nanoparticle, or a silicon nanoparticle, optionally in which the gold nanoparticle is coated with alpha-galactose and/or beta-GlcNHAc.

4. A vaccine composition according to Claim 2 or 3, in which the flavivirus peptide is attached to the nanoparticle via a linker.

5. A vaccine composition according to any preceding claim, which comprises two or more flavivirus peptides each comprising a different CD8+ T cell epitope, optionally in which each of the two or more flavivirus peptides comprises a CD8+ T cell epitope set out in SEQ ID NOs: 1 to 11 or a variant thereof.

6. A vaccine composition according to Claim 5, in which each of the two or more flavivirus peptides is attached to a nanoparticle.

7. A vaccine composition according to any preceding claim, comprising at least two flavivirus peptides comprising (i) a CD8+ T cell epitope, each of which interacts with a different HLA supertype; and/or (ii) at least one flavivirus peptide comprising a CD8+ T cell epitope that interacts with at least two different HLA supertypes.

8. A vaccine composition according to Claim 7, in which the at least two different HLA supertypes are selected from HLA-A1, HLA-A2, HLA-A3, HLA-A24, HLA-B7, HLA-B8, HLA-B27, HLA-B44, HLA-B58 and HLA-B62.

9. A vaccine composition according to Claim 8, in which the at least two different HLA supertypes are HLA-A2 and HLA-A24.

10. A vaccine composition according to any preceding claim, in which the CD8+ T cell epitope is conserved between flaviviruses.

11. A vaccine composition according to any preceding claim, in which the CD8+ T cell epitope is conserved between Zika viruses, West Nile viruses and/or Dengue viruses.

12. A vaccine composition according to any preceding claim, comprising a peptide comprising a CD4+ T cell epitope, optionally in which the CD4+ T cell epitope interacts with all HLA class II types.

13. A vaccine composition according to Claim 12, in which the CD4+ T cell epitope comprises the sequence set out in SEQ ID NO: 12 or 13.

14. A vaccine composition comprising (a) a polynucleotide that encodes a flavivirus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs: 1 to 11 or a variant thereof, or (b) the full complement of a polynucleotide that encodes a flavivirus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs: 1 to 11 or a variant thereof.

15. A vaccine composition according to any preceding claim, in which the variant differs from one of SEQ ID NOs: 1 to 11 by insertion, deletion or substitution of no more than one amino acid, optionally in which the variant differs from one of SEQ ID NOs: 1 to 11 by the conservative substitution of no more than one amino acid.

16. A vaccine composition according to any preceding claim for use in a method of preventing or treating a flavivirus infection in a subject, in which the vaccine composition is to be administered to a subject infected with, or at risk of being infected with, a flavivirus.

17. A composition for use in a method of preventing or treating a flavivirus infection in a subject, the composition comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs: 1 to 11 or a variant thereof, and the method comprising (i) stimulating CTLs obtained from a Zika virus- or Dengue virus- infected individual with the composition and (ii) providing the stimulated CTLs as passive immunotherapy to the subject.

18. A composition according to Claim 17, in which the CTLs are autologous to or HLA matched with the subject.

19. A method of diagnosing a flavivirus infection in a subject, the method comprising (i) contacting CTLs obtained from the subject with a composition comprising a flavivirus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs: 1 to 11 or a

variant thereof, and (ii) detecting the presence or absence of a CTL response to the one or more CD8+ T cell epitopes.

20. A composition for use according to Claim 17 or 18, or a method according to Claim 19, in which:

(a) the variant differs from one of SEQ ID NOs: 1 to 11 by insertion, deletion or substitution of no more than one amino acid, optionally in which the variant differs from one of SEQ ID NOs: 1 to 11 by the conservative substitution of no more than one amino acid; and/or

(b) the flavivirus infection is a Zika virus infection, West Nile virus infection and/or Dengue virus infection, optionally in which:

(I) the Zika virus infection is an African Zika virus or an Asian Zika virus infection; and/or

(II) the Dengue virus infection is a Dengue virus 1, Dengue virus 2, Dengue virus 3, or Dengue virus 4 infection.